Nadolol Dosing for Long QT Syndrome

Evidence for Nadolol Superiority

• The American College of Cardiology recommends nadolol as the only beta-blocker proven to significantly reduce arrhythmic risk across all LQTS genotypes, with a hazard ratio of 0.38 and 95% CI of 0.15-0.93, p=0.03 1, 2, 3, 4, 5

Genotype-Specific Considerations

• For LQTS1 patients, nadolol is highly effective, with a greater than 95% reduction in adverse cardiac events 1, 2, 3, 4
• For LQTS2 patients, nadolol shows superior efficacy, with a greater than 75% reduction in adverse cardiac events, and is the preferred agent 1, 2, 3, 4
• For LQTS3 females, nadolol reduces events by more than 60% 1, 2, 3, 4

Clinical Pitfalls to Avoid

• The American College of Cardiology advises against using metoprolol as first-line therapy, as it appears less effective than nadolol, propranolol, or atenolol for LQTS 1, 2, 3, 4, 5
• It is essential to monitor ongoing adequacy of beta-blockade with exertion and assess QTc changes over time 1, 2, 3, 4, 5
• Patients should avoid QT-prolonging medications concurrently, as these are potentially harmful in LQTS 1, 2, 3, 4

Maximum Tolerated Dose Concept

• If patients experience recurrent appropriate ICD shocks or breakthrough symptoms despite maximum tolerated doses of nadolol, intensification with additional medications, left cardiac sympathetic denervation, or ICD should be considered 1, 2, 3, 4